Neo-DIANA: descriptive results of a prematurely terminated phase II trial of neoadjuvant atezolizumab, chemotherapy and bevacizumab in resectable EGFR-mutated NSCLC Authors: Ana Collazo-Lorduy, Virginia Calvo, Ernest Nadal, Mariano Provencio Published: 2026 ABSTRACT Reducing postoperative recurrence remains an unmet need in locally advanced non-small-cell lung cancer (NSCLC), particularly in patients with epidermal growth factor receptor (EGFR)-mutated tumours, who are at higher risk of distant metastases after surgery; particularly brain metastases. Perioperative and neoadjuvant chemoimmunotherapy strategies have improved survival outcomes in unselected populations; however, the evidence in EGFR-mutated NSCLC remains limited because most pivotal trials—including NADIM, NADIM II, CheckMate 816, RATIONALE-315, CheckMate 77T and Neotorch—excluded patients with known EGFR mutations. This gap provides a rationale for exploring the use of anti-angiogenic agents combined with chemoimmunotherapy in a molecular subgroup that is usually less-immunoresponsive. While this strategy has demonstrated efficacy in the metastatic EGFR-mutated setting, as reported in IMpower150, ATTLAS/KCSG-LU19-04 or ORIENT-31 study, prospective evidence in resectable disease is lacking. The Neo-DIANA trial was a multicentre, open-label, non-randomised phase II clinical trial designed to investigate a neoadjuvant regimen combining atezolizumab, chemotherapy and bevacizumab, followed by surgery and adjuvant atezolizumab, in resectable stages IIIA and IIIB EGFR-mutated NSCLC. Because the trial was terminated early due to slow recruitment, no conclusions can be drawn regarding the efficacy of combination therapy in patients with resectable EGFR-mutated NSCLC. Further studies are still needed to explore perioperative strategies that may help reduce postoperative relapses in these patients. Introduction Although complete resection is achievable for many patients with early-stage or locally advanced non-small cell lung cancer (NSCLC), a substantial proportion ultimately relapses, generally with distant metastases that are incurable and fatal. Five-year overall survival remains poor—36% for stage IIIA and 26% for stage IIIB disease (1). The prognosis is even worse for patients with epidermal growth factor receptor (EGFR)-mutated tumours, which markedly increases the risk of postoperative metastatic recurrence, particularly in the brain (2). The introduction of perioperative immunotherapy has recently shifted the management of patients with resectable stage II-III NSCLC. The NADIM trials (3,4), together with multiple phase III studies (5-9), have shown increased pathological complete response (pCR) rates and improved event-free survival (EFS) when immunotherapy is added to chemotherapy in the neoadjuvant or perioperative settings. Importantly, several pivotal phase III studies have also demonstrated a statistically significant overall survival (OS) advantage over chemotherapy alone (10-12). However, it is unclear whether these benefits extend to patients with EGFR mutations, as most landmark trials excluded this subgroup. Given the scarce information available and the urgent need to reduce postoperative recurrences, further studies are needed to investigate the benefits of immunotherapy combined with anti-angiogenic therapy in patients with resectable EGFR-mutated NSCLC. Methods This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments and Good Clinical Practice per International Conference on Harmonization guidelines. The study was approved by the Independent Ethics Committee of Hospital Universitario Puerta de Hierro-Majadahonda (No. AC032/20), which served as the central Ethics Committee for all participating sites. All patients provided written informed consent before trial enrolment and were recruited at Hospital Universitario Puerta de Hierro-Majadahonda and Institut Català d’Oncologia (ICO)-Hospital Universitari de Bellvitge (HUB). In accordance with national regulations, individual ethical approval from each participating institution was not required, and all participating centres adhered to the central approval. The study was registered at EudraCT under No. 2020-000642-33. Neo-DIANA was a multicentre, open-label, non-randomised phase II clinical trial designed to evaluate the antitumor activity of an atezolizumab-based neoadjuvant strategy, followed by surgery and six cycles of adjuvant atezolizumab 1,200 mg in patients with locally advanced, potentially resectable EGFR-mutated NSCLC. The neoadjuvant regimen consisted of three cycles of atezolizumab 1,200 mg in combination with bevacizumab 15 mg/kg, carboplatin AUC6 and pemetrexed 500 mg/m2 for most participants, while those with squamous or adenosquamous histology received atezolizumab 1,200 mg plus carboplatin AUC6 and paclitaxel 200 mg/m2. Eligible participants were treatment-naïve patients with potentially resectable stages IIIA or IIIB NSCLC (according to 8th edition of the International Association for the Study of Lung Cancer staging system) harbouring EGFR-sensitizing mutations (exon 19 deletions and exon 21 L858R mutations). Patients carrying other EGFR mutations, ALK fusion oncogene, STK11 ligand alteration or ROS1 translocations were excluded. The primary endpoint was major pathological response (MPR) rate, defined as ≤10% viable cancer cells in the resected tumour and sampled lymph nodes. Secondary endpoints included overall survival (OS) rate at 12, 24 and 36 months; progression-free survival (PFS) rate at 12 months; pathological complete response (pCR) rate; downstaging rate; safety, based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, and the prognostic value of tissue and blood biomarkers. Tumour response was assessed by computed tomography (CT) scan, according to RECIST v1.1, and clinical evaluation following neoadjuvant treatment, postoperatively, every 12 weeks during adjuvant treatment, every three months during the first two years of follow-up and every six months in the third year. The estimated sample size was 26 patients with stage IIIA/IIIB EGFR-mutated NSCLC. Recruitment was expected to be completed within two years; however, the study was terminated prematurely due to slow accrual. Case presentations The key clinical features of the four participants—including baseline characteristics, treatment exposure, radiological and pathological responses, toxicity, and status at database lock—are summarised in Table 1. Individual patient trajectories during follow-up, together with relevant events, are illustrated in the swimmer plot (Figure 1). Table 1Characteristics of the cohortCharacteristicsCase No. 1Case No. 2Case No. 3Case No. 4Baseline characteristics SexMaleMaleFemaleFemale Age at diagnosis (years)62745177 RaceCaucasianCaucasianCaucasianCaucasian Smoking habitNever smokerNever smokerFormer smokerNever smoker Clinical stageIIIBIIIAIIIAIIIA HistologyAdenocarcinomaAdenocarcinomaAdenosquamousAdenocarcinoma EGFR alterationEx19delEx19delL858RL858RTreatment exposure Neoadjuvant regimen ChCarboplatin + pemetrexedCarboplatin + pemetrexedCarboplatin + paclitaxelCarboplatin + pemetrexed Anti-VEGFBevacizumabBevacizumab–Bevacizumab ICIAtezolizumabAtezolizumabAtezolizumabAtezolizumab 3 cycles completedYesYesYesYes SurgeryNoNo†LobectomyLobectomy Adjuvant treatmentNANAAtezolizumabAtezolizumabEvaluation of response after neoadjuvant treatment Radiologic responseProgressive disease‡Stable diseasePartial responseStable disease Pathological responseNANAPathological complete response40% RVTToxicity SAENot reportedNot reportedNot reportedHernia repairStatus at database lock StatusAliveAliveAliveAlive†, the patient had persistent N2 disease after neoadjuvant treatment, confirmed by PET-CT and mediastinoscopy; ‡, the patient had distant progression (bone). Ch, chemotherapy; Ex19del, exon 19 deletions; ICI, immune checkpoint inhibitor; L858R, exon 21 L858R mutation; NA, not available; PET-CT, positron emission tomography-computed tomography; RVT, residual viable tumour; SAE, serious adverse event. Characteristics of the cohort †, the patient had persistent N2 disease after neoadjuvant treatment, confirmed by PET-CT and mediastinoscopy; ‡, the patient had distant progression (bone). Ch, chemotherapy; Ex19del, exon 19 deletions; ICI, immune checkpoint inhibitor; L858R, exon 21 L858R mutation; NA, not available; PET-CT, positron emission tomography-computed tomography; RVT, residual viable tumour; SAE, serious adverse event. Swimmer plot summarising follow-up and relevant events (end of treatment or disease progression) for the four participants. Each bar represents one patient. Discussion The Neo-DIANA trial was terminated early due to slow patient accrual, with only four patients ultimately enrolled. The interest of Neo-DIANA lies not only in the perioperative use of immunotherapy in EGFR-mutated NSCLC, but in the exploration of a combined anti-angiogenic, immunotherapeutic, and chemotherapy-based approach in a biologically less immune-responsive subgroup of patients. The interconnection between VEGF signalling and immunosuppression in the tumour microenvironment provides a biological rationale for the ability of anti-angiogenic agents to enhance immunotherapy efficacy, by normalizing tumour vasculature, increasing immune effector cell infiltration, and shifting the microenvironment from an immunosuppressive to an immunostimulatory state. Although perioperative chemoimmunotherapy has shown survival benefits in an unselected NSCLC population, its efficacy in EGFR-mutated patients remains uncertain. Several landmark trials—including NADIM (3), NADIM II (4), CheckMate 816 (5), RATIONALE-315 (9), CheckMate 77T (8) or Neotorch (13)—excluded patients with EGFR mutations from their inclusion criteria, thereby limiting the available evidence. In KEYNOTE-671 trial (7), molecular testing was not mandatory, allowing the inclusion of 33 patients with EGFR-positive tumours (14 were in the pembrolizumab arm and 19 were in the placebo arm). Subgroup analysis suggested a potential EFS benefit with perioperative pembrolizumab [hazard ratio (HR), 0.09 (95% CI, 0.01 to 0.74)], with only 1 of 14 patients in the immunotherapy group experiencing recurrence, progression, or death compared with 10 of 19 in the control group. Similarly, in the AEGEAN trial (6), 51 EGFR-mutated patients were enrolled prior to a protocol amendment. Pre-planned subgroup analyses indicated a trend towards improved EFS [HR, 0.86 (95% CI, 0.35 to 2.19)] and higher pCR rate with perioperative durvalumab compared with placebo (3.8% vs. 0.0%). In parallel, the phase III NeoADAURA trial evaluated neoadjuvant osimertinib, with or without chemotherapy, versus chemotherapy alone in resectable, EGFR-mutated, stage II–IIIB NSCLC. Interim results demonstrated a significant improvement in MPR rates with osimertinib-based strategies compared with chemotherapy alone (26% vs. 25% vs. 2%; P<0.0001); along with higher EFS rates at 12 months (93%, 95% and 83%, respectively) (14). Evidence supporting the addition of anti-angiogenic therapy to chemoimmunotherapy in EGFR-mutated NSCLC has been reported in the phase III IMpower150 trial in the metastatic EGFR-mutated setting (15). In this study, OS was longer in patients treated with atezolizumab plus bevacizumab and carboplatin plus paclitaxel (ABCP) compared with bevacizumab and carboplatin plus paclitaxel (BCP) [29.4 vs. 18.1 months; HR, 0.60 (95% CI, 0.31 to 1.14)]. Two additional phase III studies supported the benefit of this strategy in the context of unresectable EGFR-mutated NSCLC upon progression on TKI therapy. In the ATTLAS/KCSG-LU19-04 trial (16), ABCP treatment improved median PFS compared with pemetrexed plus carboplatin or cisplatin (PC) [8.48 vs. 5.62 months; HR, 0.62 (95% CI, 0.45 to 0.86); P=0.004]. In the ORIENT-31 study (17), both sintilimab plus chemotherapy and sintilimab plus IBI305 (a bevacizumab biosimilar) plus chemotherapy improved PFS compared with chemotherapy alone [5.5 and 7.2 vs. 4.3 months, HR, 0.72 (95% CI, 0.55 to 0.94); P=0.016 and HR, 0.51 (95% CI, 0.39 to 0.67); P<0.0001, respectively]. Although these represent different clinical entities within EGFR-mutated NSCLC, evidence from comparable strategies in the chemoradiotherapy (CRT) setting may also be informative. A post hoc analysis of the PACIFIC trial showed that consolidation durvalumab after CRT did not confer a clear benefit in PFS or OS in the subgroup of patients with EGFR-mutant NSCLC (18). By contrast, benefit was observed with EGFR-targeted consolidation after CRT in the LAURA trial. In LAURA, osimertinib was associated with reduction in the hazard of disease progression or death versus placebo (HR, 0.16) (19). Neo-DIANA is of particular interest because, to our knowledge, no prior study has specifically evaluated the role of neoadjuvant chemoimmunotherapy combined with anti-angiogenic agents in resectable EGFR-mutated NSCLC. Owing to the low prevalence of EGFR-mutated NSCLC in Spain, the trial was prematurely terminated and only a very limited number of patients could be enrolled. This underscores the need for international collaborative studies, particularly involving countries with populations exhibiting higher rates of EGFR mutations. In view of this limitation, any apparent numerical differences must be interpreted with caution, and the findings should be regarded as hypothesis-generating only. Even so, they still support the biological and clinical rationale for further research to determine the optimal perioperative strategy for resectable EGFR-mutated disease. Supplementary The article’s supplementary files as Available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2026-0711/prf